GSE196113 SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
In this study, we investigated the effect of SARS-CoV-2 on the endothelial barrier using an airway-on-a-chip that mimics respiratory organs and found that SARS-CoV-2 produced from infected epithelial cells disrupts the barrier by decreasing Claudin-5 (CLDN5), a tight junction protein, and disrupting vascular endothelial cadherin (VE-cadherin)-mediated adherens junctions. Consistently, the gene and protein expression levels of CLDN5 in a COVID-19 patient ’s lungs were decreased. CLDN5 overexpression or Fluvastatin treatment could rescue the SARS-CoV-2-induced respiratory endothelial barrier disruption. We therefore conclu...
Source: GEO: Gene Expression Omnibus - September 22, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Systems assessment of statins hazard: Integrating in silico prediction, developmental toxicity profile and transcriptomics in zebrafish
Ecotoxicol Environ Saf. 2022 Aug 24;243:113981. doi: 10.1016/j.ecoenv.2022.113981. Online ahead of print.ABSTRACTStatins are prescribed widely as lipid-lowering agents. However, statins are associated with an increased harmful risk on public health and the ecosystem. Little is known about statins' toxicity on biological development and the underlying molecular mechanisms. We exposed zebrafish embryos to a series of statins to evaluate their development toxicity. Statins-induced embryonic developmental defects in a concentration-dependent manner. 72 h LC50 values for lovastatin, simvastatin, fluvastatin, atorvastatin, rosuv...
Source: Ecotoxicology and Environmental Safety - August 27, 2022 Category: Environmental Health Authors: Ying Han Yuanyuan Ma Junwei Tong Jingpu Zhang Changqin Hu Source Type: research
Fluvastatin promotes chondrogenic differentiation of adipose-derived mesenchymal stem cells by inducing bone morphogenetic protein 2
CONCLUSIONS: Our results suggest that fluvastatin promotes chondrogenic differentiation of hADMSCs by inducing endogenous BMP2, and that one of the mechanisms underlying the effects is inhibition of RhoA-ROCK signaling via suppression of GGPP. Fluvastatin is a safe and low-cost compound that holds promise for use in transplantation of hADMSCs for cartilage regeneration.PMID:35945639 | DOI:10.1186/s40360-022-00600-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - August 9, 2022 Category: Drugs & Pharmacology Authors: Masanari Kuwahara Yukio Akasaki Norio Goto Ichiro Kurakazu Takuya Sueishi Masakazu Toya Taisuke Uchida Tomoaki Tsutsui Ryota Hirose Hidetoshi Tsushima Yasuharu Nakashima Source Type: research
Fluvastatin promotes chondrogenic differentiation of adipose-derived mesenchymal stem cells by inducing bone morphogenetic protein 2
Adipose-derived mesenchymal stem cells (ADMSCs) are a promising source of material source for medical regeneration of cartilage. Growth factors, including transforming growth factor- β (TGFβ) subfamily members ... (Source: BMC Clinical Pharmacology)
Source: BMC Clinical Pharmacology - August 9, 2022 Category: Drugs & Pharmacology Authors: Masanari Kuwahara, Yukio Akasaki, Norio Goto, Ichiro Kurakazu, Takuya Sueishi, Masakazu Toya, Taisuke Uchida, Tomoaki Tsutsui, Ryota Hirose, Hidetoshi Tsushima and Yasuharu Nakashima Tags: Research article Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
